Scroll Top

MedVitaz Pharma Solutions Is a consulting healthcare company
Our Approach

An initiative for helping end users directly to get the right medicines and right medical treatments from the right source.

Our Philosophy

Help patient for specialized medicines and treatments of critical and Life threatening diseases.

MedVitaz Services

We work directly with a global network of approved distributors/wholesalers and audited suppliers to assure a steady and consistent supply of pharmaceutical products.

We can facilitate for procuring the medicines that are not available in India from US and European approved markets.

We can help you in taking specialized treatments for cancer, Liver& Kidney transplants, Neuro & cardiac Surgeries.

All Blood Cancer Breast Lung
TECVAYLI (teclistamab-cqyv) injection
TECVAYLI (teclistamab-cqyv) injection
Columvi (glofitamab) for injection
Columvi (glofitamab) for injection
ELREXFIO (elranatamab-bcmm) injection
ELREXFIO (elranatamab-bcmm) injection
Atriance (nelarabine) for injection
Atriance (nelarabine) for injection
VYXEOS (daunorubicin and cytarabine) liposome for injection
VYXEOS (daunorubicin and cytarabine) liposome for injection
EMPLICITI (elotuzumab) for injection
EMPLICITI (elotuzumab) for injection
RETEVMO (selpercatinib) capsules
RETEVMO (selpercatinib) capsules
XALKORI (crizotinib) capsules
XALKORI (crizotinib) capsules
ZYNLONTA (loncastuximab tesirine-lpyl) for injection
ZYNLONTA (loncastuximab tesirine-lpyl) for injection
OPDUALAG (nivolumab and relatlimab-rmbw) injection
OPDUALAG (nivolumab and relatlimab-rmbw) injection
ROLVEDON (eflapegrastim-xnst) injection
ROLVEDON (eflapegrastim-xnst) injection
VEGZELMA (bevacizumab-adcd) injection
VEGZELMA (bevacizumab-adcd) injection
BOSULIF (bosutinib) tablets
BOSULIF (bosutinib) tablets
SCEMBLIX (asciminib) tablets
SCEMBLIX (asciminib) tablets
DAURISMO (glasdegib) tablets
EXKIVITY (mobocertinib) capsules
EXKIVITY (mobocertinib) capsules
RYLAZE (asparaginase erwinia chrysanthemi (recombinant) rywn) injection
RYLAZE (asparaginase erwinia chrysanthemi (recombinant) rywn) injection
REZUROCK (belumosudil) tablets, for oral use. Initial U.S. Approval: 2021. Get Access In India
REZUROCK (belumosudil) tablets, for oral use. Initial U.S. Approval: 2021. Get Access In India
LUMAKRAS (sotorasib) tablets. Get Access In India
LUMAKRAS (sotorasib) tablets. Get Access In India
ADAKVEO (crizanlizumab-tmca) injection, for intravenous use. Initial U.S. Approval: 2019
ADAKVEO (crizanlizumab-tmca) injection, for intravenous use. Initial U.S. Approval: 2019
Bevacizumab Injection. Initial U.S. Approval: 2004
Bevacizumab Injection. Initial U.S. Approval: 2004
MONJUVI (tafasitamab-cxix) for injection. FDA-Approved. To treat lymphoma
MONJUVI (tafasitamab-cxix) for injection. FDA-Approved. To treat lymphoma
ZELBORAF (vemurafenib) tablet. FDA-Approved
ZELBORAF (vemurafenib) tablet. FDA-Approved
COTELLIC (cobimetinib) tablets. FDA-Approved
COTELLIC (cobimetinib) tablets. FDA-Approved
BLINCYTO (blinatumomab) for injection, for intravenous use. Initial U.S. Approval: 2014
BLINCYTO (blinatumomab) for injection, for intravenous use. Initial U.S. Approval: 2014
ICLUSIG (ponatinib) tablets for oral use. Initial U.S. Approval: 2012
ICLUSIG (ponatinib) tablets for oral use. Initial U.S. Approval: 2012
ONUREG (azacitidine) tablets, for oral use. Initial U.S. Approval: 2004
ONUREG (azacitidine) tablets, for oral use. Initial U.S. Approval: 2004
TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Initial U.S. Approval: 2019
TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Initial U.S. Approval: 2019
LIBTAYO (cemiplimab-rwlc) injection, for intravenous use. Initial U.S. Approval: 09/2018
LIBTAYO (cemiplimab-rwlc) injection, for intravenous use. Initial U.S. Approval: 09/2018
AVASTIN (bevacizumab) Solution for intravenous infusion. Initial U.S. Approval: 2004
AVASTIN (bevacizumab) Solution for intravenous infusion. Initial U.S. Approval: 2004
XOSPATA (gilteritinib) tablets, for oral use. Initial U.S. Approval: 2018
XOSPATA (gilteritinib) tablets, for oral use. Initial U.S. Approval: 2018
YERVOY (ipilimumab) injection, for intravenous use. Initial U.S. Approval: 2011
YERVOY (ipilimumab) injection, for intravenous use. Initial U.S. Approval: 2011
ZYDELIG (idelalisib) tablets, for oral use. Initial U.S. Approval: 2014
ZYDELIG (idelalisib) tablets, for oral use. Initial U.S. Approval: 2014
Tasigna (nilotinib) Capsules Initial U.S. Approval: 2007
Tasigna (nilotinib) Capsules Initial U.S. Approval: 2007
TAFINLAR (dabrafenib) capsules, for oral use. Initial U.S. Approval: 2013
TAFINLAR (dabrafenib) capsules, for oral use. Initial U.S. Approval: 2013
TAVALISSE (fostamatinib disodium hexahydrate) tablets, for oral use Initial U.S. Approval: 2018
TAVALISSE (fostamatinib disodium hexahydrate) tablets, for oral use Initial U.S. Approval: 2018
TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018
TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018
VENCLEXTA (venetoclax) tablets, for oral use. Initial U.S. Approval: 2016
VENCLEXTA (venetoclax) tablets, for oral use. Initial U.S. Approval: 2016
REVLIMID [lenalidomide] capsules, for oral use. Initial US Approval: 2005
REVLIMID [lenalidomide] capsules, for oral use. Initial US Approval: 2005
PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2008
PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2008
POMALYST (pomalidomide) capsules, for oral use. Initial US Approval: 2013
POMALYST (pomalidomide) capsules, for oral use. Initial US Approval: 2013
POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use. Initial U.S. Approval: 2019
POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use. Initial U.S. Approval: 2019
NINLARO (ixazomib) capsules, for oral use. Initial U.S. Approval: 2015
NINLARO (ixazomib) capsules, for oral use. Initial U.S. Approval: 2015
MEKINIST (trametinib) tablets, for oral use. Initial U.S. Approval: 2013
MEKINIST (trametinib) tablets, for oral use. Initial U.S. Approval: 2013
IMLYGIC (talimogene laherparepvec). Suspension for intralesional injection Initial U.S. Approval: 2015
IMLYGIC (talimogene laherparepvec). Suspension for intralesional injection Initial U.S. Approval: 2015
IDHIFA (enasidenib) tablets, for oral use. Initial U.S. Approval: 2017
IDHIFA (enasidenib) tablets, for oral use. Initial U.S. Approval: 2017
GAZYVA (obinutuzumab) injection, for intravenous infusion. Initial U.S. Approval: 2013
GAZYVA (obinutuzumab) injection, for intravenous infusion. Initial U.S. Approval: 2013
MULPLETA (lusutrombopag tablets) for oral use. Initial U.S. Approval: 2018
MULPLETA (lusutrombopag tablets) for oral use. Initial U.S. Approval: 2018
MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use. Initial U.S. Approval: 2000
MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use. Initial U.S. Approval: 2000
BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. Initial U.S. Approval: 2020
BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. Initial U.S. Approval: 2020
BRUKINSA (zanubrutinib) capsules, for oral use. Initial U.S. Approval: 2019
BRUKINSA (zanubrutinib) capsules, for oral use. Initial U.S. Approval: 2019
CALQUENCE (acalabrutinib) capsules, for oral use. Initial U.S. Approval: 2017
CALQUENCE (acalabrutinib) capsules, for oral use. Initial U.S. Approval: 2017
COPIKTRA (duvelisib), capsules for oral use. Initial U.S. Approval: 2018
COPIKTRA (duvelisib), capsules for oral use. Initial U.S. Approval: 2018
DARZALEX (daratumumab) injection, for intravenous use. Initial U.S. Approval – 2015
DARZALEX (daratumumab) injection, for intravenous use. Initial U.S. Approval – 2015
ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). Lyophilized powder for solution for intravenous injection. Initial U.S. Approval: 2018
ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). Lyophilized powder for solution for intravenous injection. Initial U.S. Approval: 2018
ALIQOPA (copanlisib) for injection, for intravenous use. Initial U.S. Approval: 2017
ALIQOPA (copanlisib) for injection, for intravenous use. Initial U.S. Approval: 2017
TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020
TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020
TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020
TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020
PIQRAY (alpelisib) tablets, for oral use. Initial U.S. Approval: 2019
PIQRAY (alpelisib) tablets, for oral use. Initial U.S. Approval: 2019
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020
PERJETA (pertuzumab) Injection, for intravenous use Initial U.S. Approval: 2012
PERJETA (pertuzumab) Injection, for intravenous use Initial U.S. Approval: 2012
ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use Initial U.S. Approval: 2019
ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use Initial U.S. Approval: 2019
fam-trastuzumab deruxtecan-nxki for injection, for intravenous use Initial U.S. Approval: 2019
fam-trastuzumab deruxtecan-nxki for injection, for intravenous use Initial U.S. Approval: 2019
IXEMPRA Kit (ixabepilone) for Injection, for intravenous infusion only Initial U.S. Approval: 2007
IXEMPRA Kit (ixabepilone) for Injection, for intravenous infusion only Initial U.S. Approval: 2007
KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use. Initial U.S. Approval: 2013
KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use. Initial U.S. Approval: 2013
TABRECTA (capmatinib) tablets, for oral use Initial U.S. Approval: 2020
TABRECTA (capmatinib) tablets, for oral use Initial U.S. Approval: 2020
SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019
ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019
OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014
OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014
ESBRIET (pirfenidone) capsules and film-coated tablets, for oral use Initial U.S. Approval: 2014
ESBRIET (pirfenidone) capsules and film-coated tablets, for oral use Initial U.S. Approval: 2014
KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014
KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014
Your Health Consultant

We are experienced health consultants. Our focus is sourcing FDA Approved pharmaceuticals and comparator drugs. We work directly with a global network of approved distributors/wholesalers and audited suppliers to assure a steady and consistent supply of pharmaceutical products.

1 (Demo)
PULMONARY (Medications)
Surgery, radiation, chemotherapy, targeted treatments and immunotherapy—alone or in combination—are used to treat lung cancer.
2 (Demo)
CARDIOLOGY (Medications)
Lorem ipsum dolor sit amet, consectetur aditpisicing elit, sed do eiusmod tempor.
3 (Demo)
NEUROLOGY (Medications)
Involves the evaluation and treatment of individuals with movement problems caused by disease or injury affecting the nervous...
4 (Demo)
DENTAL CARE (Medications)
Lorem ipsum dolor sit amet, consectetur aditpisicing elit, sed do eiusmod tempor.
5 (Demo)
UROLOGY (Medications)
Lorem ipsum dolor sit amet, consectetur aditpisicing elit, sed do eiusmod tempor.
6 (Demo)
EYE CARE (Medications)
Lorem ipsum dolor sit amet, consectetur aditpisicing elit, sed do eiusmod tempor.
working hours

Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Monday – Thursday: 10:00 am – 2:00 pm
Friday: 12:00 am – 3:00 pm
Saturday: 13:00 am – 3:00 pm
Sunday: 10:00 am – 2:00 pm
BOOK AN APPOINTMENT

Error: Contact form not found.

0
Oncology Medications
0
Satisfied Patients
0
HCV Medications
0
Doctor In Panel
Dr Akshay Bahadur

With reference to import of drug Carfilzomib from Germany, right from the discription of the procedure to the procurement of medicine including the duration/ availability/cost of the drugs , your functionings were very much professional. I am overwhelmed with the overall experience. Please accept my best wishes to you.

Dr Aman Kumar

We have import the Medicine (Tafinlar & Mekinist) with the help of Indian Pharma Network (New Delhi) for Shri Mahant Chand Nath ji. These both Medicines are not available in India and Mr. Neeraj Nagpal, Head Business Development had arranged all relevant documents for Import, procurement and custom clearance for our supplies for continuous six months.

need help?

Talk directly to our team, please just drop us an e-mail using the form below. We aim to get back to all messages within 24 hours.

Ask a Question
OUR LATEST  news